Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient

Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer...

Full description

Saved in:
Bibliographic Details
Published inJournal of oncology pharmacy practice Vol. 26; no. 8; p. 2031
Main Authors Sengul Samanci, Nilay, Celik, Emir, Akovalı, Burak, Sager, Sait, Demirelli, Fuat Hulusi
Format Journal Article
LanguageEnglish
Published England 01.12.2020
Subjects
Aged
Anaplastic Lymphoma Kinase - antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung - drug therapy
Female
Humans
Lung Neoplasms - drug therapy
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
Sulfones - therapeutic use
EML4-ALK
ceritinib
Non-small cell lung cancer
Online AccessGet more information

Cover

More Information
Summary:Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC). She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event. Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.
ISSN:1477-092X
DOI:10.1177/1078155220919172